SAN MATEO, Calif., July 17 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today that Bruce A. Peacock has resigned from his roles as Audit Committee chairman and director to focus on his responsibilities as CEO of privately-held Alba Therapeutics.
Tony DiTonno, NeurogesX CEO commented, “We would like to thank Bruce for all his contributions to NeurogesX during the initial regulatory approval and E.U. partnership discussions surrounding Qutenza. We are disappointed in his resignation but certainly understand the rationale and wish him well in his future endeavors.”
Consistent with Listing Rule 5605(c)(4)(B) the company has until the earlier of its next annual shareholders’ meeting or June 29, 2010 to name a third director as a member of the Audit Committee so that the company regains compliance with the requirements of Listing Rule 5605(c)(2)(A).
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX’ late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.
NeurogesX’ early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.
SOURCE NeurogesX, Inc.
CONTACT: Stephen Ghiglieri, Chief Financial Officer of NeurogesX, Inc.,
+1-650-358-3310; or investors, Sara Pellegrino, +1-646-536-7002,
spellegrino@theruthgroup.com, or media, Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, or Janine McCargo, +1-646-536-7033,
jmccargo@theruthgroup.com, all of The Ruth Group, for NeurogesX, Inc.
